NZ627995A - ß-arrestin effectors and compositions and methods of use thereof - Google Patents
ß-arrestin effectors and compositions and methods of use thereofInfo
- Publication number
- NZ627995A NZ627995A NZ627995A NZ62799513A NZ627995A NZ 627995 A NZ627995 A NZ 627995A NZ 627995 A NZ627995 A NZ 627995A NZ 62799513 A NZ62799513 A NZ 62799513A NZ 627995 A NZ627995 A NZ 627995A
- Authority
- NZ
- New Zealand
- Prior art keywords
- pro
- hypertension
- peptide
- post
- subject
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 102000000072 beta-Arrestins Human genes 0.000 title 1
- 108010080367 beta-Arrestins Proteins 0.000 title 1
- 239000012636 effector Substances 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 6
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 3
- 206010019280 Heart failures Diseases 0.000 abstract 2
- 230000006641 stabilisation Effects 0.000 abstract 2
- 238000011105 stabilization Methods 0.000 abstract 2
- XVZCRZKWBNBSQS-DGPROHSZSA-N (2S)-2-amino-3,3-dimethylbutanoic acid Chemical compound CC(C)(C)[C@H](N)C(O)=O.CC(C)(C)[C@H](N)C(O)=O XVZCRZKWBNBSQS-DGPROHSZSA-N 0.000 abstract 1
- LDRFQSZFVGJGGP-GSVOUGTGSA-N 3-hydroxy-L-valine Chemical compound CC(C)(O)[C@H](N)C(O)=O LDRFQSZFVGJGGP-GSVOUGTGSA-N 0.000 abstract 1
- 101150059573 AGTR1 gene Proteins 0.000 abstract 1
- 206010002383 Angina Pectoris Diseases 0.000 abstract 1
- 206010007556 Cardiac failure acute Diseases 0.000 abstract 1
- 206010007559 Cardiac failure congestive Diseases 0.000 abstract 1
- 206010058842 Cerebrovascular insufficiency Diseases 0.000 abstract 1
- 208000035473 Communicable disease Diseases 0.000 abstract 1
- 206010056370 Congestive cardiomyopathy Diseases 0.000 abstract 1
- XUJNEKJLAYXESH-UWTATZPHSA-N D-Cysteine Chemical compound SC[C@@H](N)C(O)=O XUJNEKJLAYXESH-UWTATZPHSA-N 0.000 abstract 1
- QNAYBMKLOCPYGJ-UWTATZPHSA-N D-alanine Chemical compound C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 abstract 1
- 201000010046 Dilated cardiomyopathy Diseases 0.000 abstract 1
- 208000007530 Essential hypertension Diseases 0.000 abstract 1
- 206010018985 Haemorrhage intracranial Diseases 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 206010020802 Hypertensive crisis Diseases 0.000 abstract 1
- 206010055171 Hypertensive nephropathy Diseases 0.000 abstract 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 abstract 1
- 206010024119 Left ventricular failure Diseases 0.000 abstract 1
- 208000009525 Myocarditis Diseases 0.000 abstract 1
- 206010067598 Neurogenic hypertension Diseases 0.000 abstract 1
- 206010062886 Procedural hypertension Diseases 0.000 abstract 1
- 201000003099 Renovascular Hypertension Diseases 0.000 abstract 1
- 208000002223 abdominal aortic aneurysm Diseases 0.000 abstract 1
- 230000001154 acute effect Effects 0.000 abstract 1
- 206010000891 acute myocardial infarction Diseases 0.000 abstract 1
- 125000000539 amino acid group Chemical group 0.000 abstract 1
- 208000007474 aortic aneurysm Diseases 0.000 abstract 1
- LDRFQSZFVGJGGP-UHFFFAOYSA-N beta-hydroxy-L-valine Natural products CC(C)(O)C(N)C(O)=O LDRFQSZFVGJGGP-UHFFFAOYSA-N 0.000 abstract 1
- 208000026106 cerebrovascular disease Diseases 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000000004 hemodynamic effect Effects 0.000 abstract 1
- 208000015210 hypertensive heart disease Diseases 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 abstract 1
- 201000005857 malignant hypertension Diseases 0.000 abstract 1
- 201000011461 pre-eclampsia Diseases 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cardiology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Virology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261592887P | 2012-01-31 | 2012-01-31 | |
| PCT/US2013/023808 WO2013116312A1 (en) | 2012-01-31 | 2013-01-30 | ß-ARRESTIN EFFECTORS AND COMPOSITIONS AND METHODS OF USE THEREOF |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ627995A true NZ627995A (en) | 2016-12-23 |
Family
ID=48870731
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ627995A NZ627995A (en) | 2012-01-31 | 2013-01-30 | ß-arrestin effectors and compositions and methods of use thereof |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US8946142B2 (enExample) |
| EP (1) | EP2809337A4 (enExample) |
| JP (1) | JP6225121B2 (enExample) |
| KR (1) | KR20140132340A (enExample) |
| CN (1) | CN104168907A (enExample) |
| AU (1) | AU2013215269A1 (enExample) |
| BR (1) | BR112014018709A8 (enExample) |
| CA (1) | CA2862933A1 (enExample) |
| EA (1) | EA201491455A1 (enExample) |
| HK (1) | HK1203379A1 (enExample) |
| IL (1) | IL233826A0 (enExample) |
| MX (1) | MX2014009233A (enExample) |
| NZ (1) | NZ627995A (enExample) |
| WO (1) | WO2013116312A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA201491455A1 (ru) * | 2012-01-31 | 2015-01-30 | Тревена, Инк. | ЭФФЕКТОРЫ β-АРРЕСТИНА, КОМПОЗИЦИИ, ИХ СОДЕРЖАЩИЕ, И СПОСОБЫ ИХ ПРИМЕНЕНИЯ |
| EP3208861A1 (en) | 2016-02-19 | 2017-08-23 | Novaled GmbH | Electron transport layer comprising a matrix compound mixture for an organic light-emitting diode (oled) |
| US11116737B1 (en) | 2020-04-10 | 2021-09-14 | University Of Georgia Research Foundation, Inc. | Methods of using probenecid for treatment of coronavirus infections |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3925345A (en) * | 1974-05-10 | 1975-12-09 | Francis Merlin Bumpus | (sar' 1',thr' 8'+9 angiotensin ii as an angiotensin antagonist |
| US3932624A (en) | 1974-06-17 | 1976-01-13 | Morton-Norwich Products, Inc. | Method for prolonging the inhibitory effect of saralasin on angiotensin II |
| JPS5825980B2 (ja) | 1976-02-12 | 1983-05-31 | ヤマサ醤油株式会社 | サイクリックヌクレオチドの定量法 |
| US4547489A (en) | 1984-06-11 | 1985-10-15 | Ortho Pharmaceutical Corporation | Conformationally restricted thymopentin-like compounds |
| US5182264A (en) | 1986-03-07 | 1993-01-26 | Schering Corporation | Angiotensin II receptor blockers as antiglaucoma agents |
| EP0358418B1 (en) * | 1988-09-05 | 1992-12-16 | Sankyo Company Limited | Cyclic peptide, its preparation and its use in the treatment of cardiovascular disorders |
| GB8822483D0 (en) | 1988-09-24 | 1988-10-26 | Medical Res Council | Developments relating to mas oncogene |
| US5401629A (en) | 1990-08-07 | 1995-03-28 | The Salk Institute Biotechnology/Industrial Associates, Inc. | Assay methods and compositions useful for measuring the transduction of an intracellular signal |
| CA2090401A1 (en) | 1990-08-27 | 1992-02-28 | Deborah A. Rathjen | Method of treating viral infection |
| AU1256692A (en) | 1991-02-06 | 1992-09-07 | Schering Corporation | Combination of an angiotensin II antagonist or renin inhibitor with a neutral endopeptidase inhibitor |
| PT730465E (pt) | 1993-09-24 | 2002-06-28 | Univ Southern California | Utilizacao de angiotensina iii e de analogos desta em cicatrizacao de tecidos |
| US5955430A (en) | 1993-09-24 | 1999-09-21 | University Of Southern California | Use of angiotensin II fragments and analogs thereof in tissue repair |
| US5958884A (en) | 1997-04-11 | 1999-09-28 | The Brigham And Women's Hospital, Inc. | Compositions and methods for treating erectile dysfunction |
| US6165978A (en) | 1997-12-12 | 2000-12-26 | University Of Southern California | Wound healing composition |
| US20040214836A1 (en) | 1998-05-29 | 2004-10-28 | Cheresh David A. | Method of treatment of myocardial infarction |
| US6362371B1 (en) | 1998-06-08 | 2002-03-26 | Advanced Medicine, Inc. | β2- adrenergic receptor agonists |
| US20050202029A1 (en) | 2003-10-03 | 2005-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Family of cystatin-related chemoattractant proteins |
| US20070286863A1 (en) | 2006-05-17 | 2007-12-13 | Christopher Sinal | CMKLR regulation of adipogenesis and adipocyte metabolic function |
| WO2008130217A1 (en) | 2006-08-08 | 2008-10-30 | Applied Nanosystems B.V. | Cyclic angiotensin analogs |
| GB0705488D0 (en) | 2007-03-22 | 2007-05-02 | Isis Innovation | Treatment of inflammation and/or endotoxic shock |
| US8038992B2 (en) | 2008-05-10 | 2011-10-18 | The Board Of Trustees Of The Leland Stanford Junior University | Target for regulating multiple sclerosis |
| US20100092974A1 (en) | 2008-08-15 | 2010-04-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for screening for modulators of ccrl2 |
| CN102333536B (zh) * | 2008-12-29 | 2014-08-13 | 特维那公司 | β-抑制蛋白效应器和组合物以及其应用方法 |
| US8293925B2 (en) | 2009-09-21 | 2012-10-23 | Chemocentryx, Inc. | Pyrrolidinone carboxamide derivatives |
| JP5925771B2 (ja) * | 2010-06-24 | 2016-05-25 | トラスティーズ オブ タフツ カレッジ | ナイアシン模倣体、およびその使用方法 |
| EA201491455A1 (ru) * | 2012-01-31 | 2015-01-30 | Тревена, Инк. | ЭФФЕКТОРЫ β-АРРЕСТИНА, КОМПОЗИЦИИ, ИХ СОДЕРЖАЩИЕ, И СПОСОБЫ ИХ ПРИМЕНЕНИЯ |
-
2013
- 2013-01-30 EA EA201491455A patent/EA201491455A1/ru unknown
- 2013-01-30 KR KR20147023251A patent/KR20140132340A/ko not_active Withdrawn
- 2013-01-30 CN CN201380014614.9A patent/CN104168907A/zh active Pending
- 2013-01-30 AU AU2013215269A patent/AU2013215269A1/en not_active Abandoned
- 2013-01-30 MX MX2014009233A patent/MX2014009233A/es unknown
- 2013-01-30 BR BR112014018709A patent/BR112014018709A8/pt active Search and Examination
- 2013-01-30 HK HK15103956.9A patent/HK1203379A1/xx unknown
- 2013-01-30 JP JP2014555666A patent/JP6225121B2/ja not_active Expired - Fee Related
- 2013-01-30 WO PCT/US2013/023808 patent/WO2013116312A1/en not_active Ceased
- 2013-01-30 EP EP13743852.9A patent/EP2809337A4/en not_active Withdrawn
- 2013-01-30 NZ NZ627995A patent/NZ627995A/en not_active IP Right Cessation
- 2013-01-30 CA CA2862933A patent/CA2862933A1/en not_active Abandoned
- 2013-01-31 US US13/755,637 patent/US8946142B2/en not_active Expired - Fee Related
-
2014
- 2014-07-27 IL IL233826A patent/IL233826A0/en unknown
- 2014-12-22 US US14/579,956 patent/US20150105316A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2015506960A (ja) | 2015-03-05 |
| CN104168907A (zh) | 2014-11-26 |
| US20130196902A1 (en) | 2013-08-01 |
| WO2013116312A1 (en) | 2013-08-08 |
| AU2013215269A1 (en) | 2014-08-21 |
| EP2809337A1 (en) | 2014-12-10 |
| US8946142B2 (en) | 2015-02-03 |
| CA2862933A1 (en) | 2013-08-08 |
| BR112014018709A2 (enExample) | 2017-06-20 |
| EA201491455A1 (ru) | 2015-01-30 |
| BR112014018709A8 (pt) | 2017-07-11 |
| JP6225121B2 (ja) | 2017-11-01 |
| HK1203379A1 (en) | 2015-10-30 |
| MX2014009233A (es) | 2015-05-15 |
| US20150105316A1 (en) | 2015-04-16 |
| IL233826A0 (en) | 2014-09-30 |
| KR20140132340A (ko) | 2014-11-17 |
| EP2809337A4 (en) | 2016-05-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ628446A (en) | Fibronectin based scaffold domain proteins that bind to myostatin | |
| NZ610091A (en) | Antibodies | |
| NZ623576A (en) | Tfpi inhibitors and methods of use | |
| NZ708144A (en) | Recombinant adenoviruses and use thereof | |
| MX384984B (es) | Proteinas de union del miembro 1 de la familia de transmembrana 4 l-seis (tm4sf1) y metodos de uso de las mismas. | |
| WO2014022376A3 (en) | Treatment of pulmonary arterial hypertension with prostacyclin-treated endothelial progenitor cells | |
| NZ601591A (en) | Methods for treating pancreatic cancer | |
| MY159013A (en) | Recombinant protein production in avian ebx® cells | |
| NZ612272A (en) | Anti-cd38 antibodies | |
| WO2016004906A3 (zh) | 一种肿瘤血管阻断剂多肽、基因、表达载体及其应用 | |
| MX2015014608A (es) | Novedosas moleculas de union biespecifica con actividad antitumoral. | |
| NZ628625A (en) | Polypeptides binding to human complement c5 | |
| NZ590050A (en) | Fgf21 mutants and uses thereof | |
| WO2012082056A8 (en) | Novel biomarker and uses thereof in diagnosis, treatment of autism | |
| MX2019008949A (es) | Agente terapeutico para cardiomiopatia, infarto al miocardio antiguo e insuficiencia cardiaca cronica. | |
| NZ703093A (en) | Purification of iduronate-2-sulfatase | |
| MY165160A (en) | TREATMENT OF MYOCARDIAL INFARCTION USING TGF-ß ANTAGONISTS | |
| NZ599604A (en) | Synthetic myostatin peptide antagonists | |
| NZ627995A (en) | ß-arrestin effectors and compositions and methods of use thereof | |
| IN2014DN09963A (enExample) | ||
| MX378784B (es) | Proteína. | |
| NZ609474A (en) | Fviii peptides for immune tolerance induction and immunodiagnostics | |
| EA201492068A1 (ru) | Гидрохлоридная соль пептида и ее применение в комбинации с другими пептидами в иммунотерапии | |
| NZ629291A (en) | Anti-robo4-antibody | |
| RU2014114790A (ru) | Новый вариант альфа-1-антитрипсина, способ его получения и применения |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 30 JAN 2020 BY FB RICE Effective date: 20170412 |
|
| LAPS | Patent lapsed |